AbbVie Beats Antitrust Challenge To Humira 'Patent Thicket'

By Lauraann Wood · June 8, 2020, 7:02 PM EDT

Humira buyers have alleged neither an antitrust violation nor an antitrust injury in their novel lawsuit claiming AbbVie built a "patent thicket" around its immunosuppressant drug Humira to block cheaper biosimilars...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

In Re: Humira (Adalimumab) Antitrust Litigation

Case Number

Court

Illinois Northern

Nature of Suit

410(Anti-Trust)

Date Filed

March 18, 2019

Recent Articles By Lauraann

July 01, 2024
Ill., Northshore Say Anti-Vax Case Not About Religious Liberty
June 20, 2024
$13B Antitrust Suit Is Class Cert 'Antithesis,' Delta Dental Says
June 07, 2024
Chicago-Area Man Charged With $60M COVID Test Fraud
May 22, 2024
Nursing Home Asks Ill. Justices For Broad COVID Immunity
May 20, 2024
Northshore Unit Beats Employee's Vaccine Exemption Suit
May 06, 2024
UChicago Can't Ditch Data Sharing Privacy Claim
April 25, 2024
Becton BIPA Suit Gets Cut Short Under Health Exception
April 19, 2024
Northshore Health Worker Drops Genetic Info Privacy Claims
April 01, 2024
'Unreliable' Theory Dooms City's Acthar Antitrust Cert. Bid
March 26, 2024
Pharmacy Owner Gets 42 Months For $25M Kickback Scam